摘要:
A process for quantification of cell populations or subpopulations, by incubating a sample with labelled antibodies directed against characteristic surface antigens of the cell population to be quantified to form labelled antibody/antigen complexes. Standards with known, differing particle concentration and having comparable sedimentation behaviour to the cells to be determined and further, carrying molecules which are directed against the labelled antibody or a part hereof are also incubated with the labelled antibodies. The cells of the sample solution, as well as the particles of the standard solution, are separated off from the excess labelled antibodies and the amount of the labelling is measured not only on the cells but also on the particles. By comparison of the measurement value from the sample with the measurement values from the standard solutions, there is ascertained the number of cells to be determined in the sample. The standard and a reagent kit for carrying out the process are also the subject of this application.
摘要:
A process for quantification of cell populations or subpopulations, by incubating a sample with labelled antibodies directed against characteristic surface antigens of the cell population to be quantified to form labelled antibody/antigen complexes. Standards with known, differing particle concentration and having comparable sedimentation behavior to the cells to be determined and further, carrying molecules which are directed against the labelled antibody or a part hereof are also incubated with the labelled antibodies. The cells of the sample solution, as well as the particles of the standard solution, are separated off from the excess labelled antibodies and the amount of the labelling is measured not only on the cells but also on the particles. By comparison of the measurement value from the sample with the measurement values from the standard solutions, there is ascertained the number of cells to be determined in the sample. The standard and a reagent kit for carrying out the process are also the subject of this application.
摘要:
The present invention provides a human monoclonal antibody against melanoma, characterized in that it binds to the gangliosides GM3 and GD3 but essentially does not bind to the gangliosides GM1, GM2, GD1a, GD1b and GD2, the binding of the antibody to the gangliosides having been determined by immune staining after thin layer chromatographic separation of the gangliosides. The present invention also provides a process for the production of human monoclonal antibodies directed against melanoma, wherein, without previous immunization, B-lymphocytes are isolated from a healthy person, the isolated B-lymphocytes are immortalized, antibodies from the immortalized B-lymphocytes are screened by immune-histochemical analysis for binding against melanoma and/or melanoma metastases, the positively reacting B-lymphocytes are selected, cultured and monoclonal antibodies obtained therefrom.
摘要:
The invention concerns autoreactive peptides, peptide-MHC complexes, T cell subpopulations that react thereto as well as diagnostic and therapeutic applications of these compounds.
摘要:
The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc &ggr; and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells. The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.
摘要:
The invention concerns autoreactive peptides, peptide-MHC complexes, T cell subpopulations that react thereto as well as diagnostic and therapeutic applications of these compounds.
摘要:
The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc .gamma. and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells.The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.
摘要:
An antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
摘要翻译:与IL-13Rα1结合的抗体,抑制IL-13生物活性并包含可变重链和可变轻链,其特征在于所述抗体的可变重链氨基酸序列CDR3选自重链CDR3序列 的SEQ ID NO:1,3,5,7或9可用于治疗哮喘和过敏性疾病。
摘要:
The current invention describes a nucleic acid comprising in a 5′ to 3′ direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5′ splice donor site and terminated by a 3′ splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.
摘要:
An antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.
摘要翻译:与IL-13Rα1结合的抗体,抑制IL-13生物活性并包含可变重链和可变轻链的抗体,其特征在于所述抗体的可变重链氨基酸序列CDR3选自重链CDR3序列 的SEQ ID NO:1,3,5,7或9可用于治疗哮喘和过敏性疾病。